Multiple System Atrophy (MSA) Market is expected to reach US$ 202.3 Million by 2031, Report by CoherentMI
14. Oktober 2024 11:03 ET
|
CMI
Burlingame, Oct. 14, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, Multiple System Atrophy (MSA) Market is estimated to value at US$ 148.1 Million in the year 2024, and is...
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
17. Juli 2024 07:35 ET
|
ALTERITY THERAPEUTICS LIMITED
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers...
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
17. Juli 2024 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated...
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
29. Mai 2024 19:21 ET
|
ALTERITY THERAPEUTICS LIMITED
- New bioMUSE Data Informs ATH434-202 Study Endpoints - - Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt University - MELBOURNE, Australia and SAN FRANCISCO, May ...
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
08. Mai 2024 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) --...
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
30. April 2024 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
Highlights ATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progressionPresented promising nonclinical data on ATH434 in a primate model of Parkinson’s...
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
17. April 2024 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2 Baseline Data Confirm Approach to Target Biomarkers for Slowing...
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
10. April 2024 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
26. März 2024 10:25 ET
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company...
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
20. Februar 2024 10:25 ET
|
ALTERITY THERAPEUTICS LIMITED
– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2...